Gail Javitt Quoted in “Gene Genies: Cambridge is the Epicenter of the Gene-Editing Revolution”

Boston Business Journal

Gail H. Javitt, a Member of the Firm in the Health Care and Life Sciences practice, in the Washington, DC, office, was quoted in the Boston Business Journal, in “Gene Genies: Cambridge is the Epicenter of the Gene-Editing Revolution.” (Read the full version – subscription required.)

Following is an excerpt:

Editas Medicine is a money-losing biotech startup located across from a shopping mall in a former industrial zone in East Cambridge. It has no approved drugs, and has yet to even test one of its experimental drugs in humans.

Yet it’s worth $1 billion.

What’s more, that figure might actually undersell the potential of the company’s technology, which is expected to transform not only how we treat genetic diseases, but how we view ourselves. …

“It’s hard to be first,” said Gail Javitt, a Washington, D.C.-based lawyer who advises drug companies on FDA regulations. “It’s unavoidable that there will be a learning curve on both sides.”

Investors will be watching closely.